Complete Response After One Cycle of Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma: Two High-Risk Contexts, Child-Pugh Class B and Advanced Age

晚期肝细胞癌患者接受阿特珠单抗联合贝伐珠单抗治疗一个疗程后达到完全缓解:两种高危因素,Child-Pugh B级和高龄

阅读:1

Abstract

Complete responses after one cycle of atezolizumab-bevacizumab have been described, but evidence in two high-risk contexts - patients with Child-Pugh class B liver function and very old adults - is scarce. We report two illustrative cases of advanced hepatocellular carcinoma where radiographic complete response was observed after a single treatment cycle. Case 1 involved a patient with Child-Pugh class B liver function; Case 2 involved an older adult. For both cases, we summarize baseline characteristics, serial imaging, and tumor-marker trajectories that corroborate response after minimal exposure to therapy. Radiologic responses were assessed on multiphasic contrast-enhanced CT according to mRECIST; tumor-marker declines supported but did not determine the classification. These two cases do not establish efficacy or safety in these populations; rather, they are descriptive observations showing that such responses can occasionally occur after one treatment cycle and should be interpreted with appropriate caution. Given limited data and safety considerations in Child-Pugh class B and very old patients, the findings should not be generalized without further validation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。